Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Analysis of Investments

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities

Regeneron Pharmaceuticals Inc., adjustment to net income

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income (as reported)
Add: Unrealized gain (loss) on debt securities
Net income (adjusted)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


Reported net income experienced volatility over the five-year period, beginning at US$8,075.3 million in 2021, decreasing to US$4,338.4 million in 2022, and then fluctuating between approximately US$3.95 billion and US$4.5 billion through 2025. Adjusted net income mirrors this trend, though the magnitude of the fluctuations is smaller. The difference between reported and adjusted net income appears to be consistently related to mark-to-market adjustments on available-for-sale securities.

Net Income Trend
Reported net income declined significantly in 2022, representing a 46.4% decrease from 2021. Subsequent years show a recovery, but not to the levels observed in 2021. The increase from 2022 to 2023 was 9.1%, from 2023 to 2024 was 11.7%, and from 2024 to 2025 was 3.7%. This suggests a slowing rate of growth in net income.
Adjustment Impact
The adjustment to net income, stemming from mark-to-market changes in available-for-sale securities, consistently reduces reported net income. The adjustment amount varied between US$56.4 million (2021) and US$73.8 million (2023). This indicates that changes in the fair value of these securities have a recurring, though relatively modest, impact on the company’s reported earnings. The adjustment was smallest in 2025 at US$83.0 million.
Consistency of Adjustment
The presence of an adjustment each year suggests a consistent investment strategy involving available-for-sale securities. The relatively stable dollar amount of the adjustment, despite fluctuations in reported net income, implies that the portfolio of available-for-sale securities is managed with a degree of consistency, or that gains and losses tend to offset each other over time.

In summary, while reported net income demonstrates some volatility, the impact of mark-to-market adjustments on available-for-sale securities is a consistent, though not substantial, factor influencing the final reported earnings figure. The adjustments consistently reduce reported net income by a relatively small amount each year.


Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)

Regeneron Pharmaceuticals Inc., adjusted profitability ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The profitability ratios demonstrate a consistent pattern of adjustment impacting reported values between 2021 and 2025. While reported profitability metrics initially decline, the adjustments applied result in a smaller degree of reduction, suggesting the impact of mark-to-market adjustments on available-for-sale securities is a contributing factor to the difference between reported and adjusted figures.

Net Profit Margin
Reported net profit margin experienced a substantial decrease from 50.25% in 2021 to 31.41% in 2025. The adjusted net profit margin mirrors this downward trend, moving from 49.89% to 31.99% over the same period. The difference between reported and adjusted values remains relatively stable, fluctuating between approximately 0.3 and 1.7 percentage points annually, indicating a consistent, though modest, impact from the adjustments.
Return on Equity (ROE)
A significant decline is observed in reported ROE, falling from 43.03% in 2021 to 14.41% in 2025. The adjusted ROE follows a similar trajectory, decreasing from 42.72% to 14.68% during the same timeframe. The adjustments consistently lower the reported ROE, with the difference widening slightly over the period, moving from approximately 0.3 percentage points in 2021 to 0.25 percentage points in 2025. This suggests that changes in equity values related to available-for-sale securities are influencing the overall ROE calculation.
Return on Assets (ROA)
Reported ROA decreased from 31.75% in 2021 to 11.11% in 2025. The adjusted ROA also exhibits a downward trend, declining from 31.53% to 11.31% over the same period. The difference between reported and adjusted ROA is relatively consistent, ranging between 0.2 and 0.48 percentage points annually. This indicates a consistent, albeit small, impact from the adjustments on the asset base’s profitability.
Overall Trends
Across all three ratios, a clear downward trend is evident in both reported and adjusted values. The adjustments consistently reduce the reported profitability metrics, suggesting that mark-to-market adjustments related to available-for-sale securities are contributing to the observed declines. The relatively stable difference between reported and adjusted figures indicates a consistent, rather than accelerating, impact from these adjustments.

Regeneron Pharmaceuticals Inc., Profitability Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in thousands)
Net income
Revenues
Profitability Ratio
Net profit margin1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net income
Revenues
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Net profit margin = 100 × Net income ÷ Revenues
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income ÷ Revenues
= 100 × ÷ =


The period under review demonstrates fluctuations in both reported and adjusted net income, which correspondingly impact net profit margins. While both metrics move in tandem, a consistent difference exists between reported and adjusted figures, suggesting the presence of non-recurring items impacting reported results.

Reported Net Income & Margin
Reported net income decreased significantly from US$8,075.3 million in 2021 to US$4,338.4 million in 2022. This decline is reflected in the reported net profit margin, which fell from 50.25% to 35.64% over the same period. Subsequent years show a moderate recovery, with reported net income reaching US$4,504.9 million by 2025 and the reported net profit margin stabilizing between 31.07% and 31.41% from 2023 onwards. The initial decline followed by stabilization suggests a potential one-time impact in 2022, followed by a return to a more consistent performance level.
Adjusted Net Income & Margin
Adjusted net income mirrors the trend of reported net income, decreasing from US$8,018.9 million in 2021 to US$4,124.8 million in 2022. The adjusted net profit margin also decreased, moving from 49.89% to 33.89% during the same timeframe. Similar to reported figures, adjusted net income shows a recovery, reaching US$4,587.9 million in 2025. The adjusted net profit margin exhibits a more gradual increase, stabilizing between 31.35% and 31.99% from 2023 to 2025. The consistency in adjusted figures suggests underlying operational performance is relatively stable, despite fluctuations in reported results.
Relationship Between Reported and Adjusted Margins
A consistent difference is observed between the reported and adjusted net profit margins throughout the period. This difference ranges from approximately 0.36% to 1.36%, indicating that adjustments consistently add back to net income. This suggests the presence of items impacting reported net income that are considered non-recurring or unusual from an analytical perspective. The magnitude of the difference remains relatively stable, implying a consistent approach to adjustments.
Overall Trend
The period began with strong profitability, as indicated by high net profit margins in 2021. A substantial decrease in profitability occurred in 2022 for both reported and adjusted metrics. From 2023 onwards, a period of stabilization and modest recovery is observed, with both reported and adjusted net profit margins converging around the 31-32% range. This suggests a return to a more sustainable level of profitability following the initial downturn.

Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in thousands)
Net income
Stockholders’ equity
Profitability Ratio
ROE1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net income
Stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income ÷ Stockholders’ equity
= 100 × ÷ =


The period under review demonstrates a notable shift in profitability metrics, as evidenced by both reported and adjusted return on equity (ROE). A general decline in ROE is observed from 2021 through 2025, although with some stabilization in the later years. While reported net income fluctuates, adjusted net income presents a more consistent, albeit still generally decreasing, pattern.

Reported ROE
Reported ROE experiences a substantial decrease from 43.03% in 2021 to 14.41% in 2025. The most significant drop occurs between 2021 and 2022, falling to 19.14%. Subsequent declines are more moderate, with values of 15.22%, 15.03%, and finally 14.41% in 2023, 2024, and 2025 respectively. This suggests a diminishing ability to generate profit from shareholder equity using reported figures.
Adjusted ROE
Adjusted ROE mirrors the trend of reported ROE, decreasing from 42.72% in 2021 to 14.68% in 2025. Similar to the reported ROE, the largest decrease is observed between 2021 and 2022, with a value of 18.20%. The rate of decline slows in subsequent years, reaching 15.83% in 2023, 15.28% in 2024, and 14.68% in 2025. The adjusted ROE consistently remains slightly below the reported ROE throughout the period.
Net Income Comparison
Reported net income decreases from US$8,075,300 in 2021 to US$4,338,400 in 2022, then stabilizes around US$3,953,600 and US$4,412,600 for 2023 and 2024, respectively, before increasing slightly to US$4,504,900 in 2025. Adjusted net income follows a similar pattern, starting at US$8,018,900 in 2021, decreasing to US$4,124,800 in 2022, and then exhibiting a more gradual increase to US$4,587,900 in 2025. The difference between reported and adjusted net income is relatively small across all years, indicating that adjustments are not materially impacting overall profitability.

The consistent decline in both reported and adjusted ROE, despite relatively stable net income in later years, suggests a potential increase in equity or a decrease in the efficiency with which equity is utilized to generate profits. Further investigation into the components of equity and asset turnover would be necessary to determine the underlying drivers of this trend.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in thousands)
Net income
Total assets
Profitability Ratio
ROA1
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net income
Total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net income ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income ÷ Total assets
= 100 × ÷ =


The period under review demonstrates a fluctuating pattern in both reported and adjusted net income, which correspondingly impacts return on assets. While adjusted net income remains consistently close to reported net income, a detailed examination of the adjusted return on assets (ROA) reveals key trends.

Reported ROA Trend
Reported ROA experienced a significant decline from 31.75% in 2021 to 14.85% in 2022. This downward trend continued, albeit at a slower pace, reaching 11.95% in 2023. A slight recovery to 11.69% was observed in 2024, followed by a further decrease to 11.11% in 2025. The overall trend indicates a substantial and sustained reduction in reported ROA over the five-year period.
Adjusted ROA Trend
The adjusted ROA mirrors the trend observed in the reported ROA, beginning at 31.53% in 2021 and decreasing to 14.12% in 2022. A moderate increase is noted in 2023, with the adjusted ROA reaching 12.43%. Similar to the reported ROA, 2024 saw a slight improvement to 11.88%, but this was followed by a decline to 11.31% in 2025. The adjusted ROA consistently remains slightly below the reported ROA for each year.
Relationship between Net Income and ROA
The substantial drop in ROA between 2021 and 2022 aligns with the significant decrease in both reported and adjusted net income during the same period. While net income shows some recovery in subsequent years, it does not fully translate into a corresponding recovery in ROA, suggesting potential changes in the asset base impacting overall returns. The relatively stable adjusted net income from 2022 through 2025 suggests that the primary driver of the ROA fluctuations is likely related to asset management or efficiency rather than core profitability.
Overall Performance
The consistent decline in ROA, despite relatively stable adjusted net income in the later years of the period, warrants further investigation into the company’s asset utilization and efficiency. The difference between reported and adjusted ROA is minimal, indicating that adjustments to net income have a limited impact on the overall return on assets metric.